BioSpace News Archive

Following a nearly decade-long effort, Delcath Systems finally won the FDA’s greenlight for its Hepzato Kit for the liver-directed treatment of adult patients with metastatic uveal melanoma.

The clinical trial testing Seagen’s tyrosine kinase inhibitor Tukysa, in combination with Genentech’s Kadcyla, met the primary endpoint of progression-free survival in HER-2 breast cancer patients.

The regulator informed bluebird bio that it will not convene an advisory committee meeting to discuss the company’s application for the gene therapy being developed for sickle cell disease.

Amid strong performance in the first half of 2023, Stada Arzneimittel’s private equity owners are considering a potential sale, though there are still no definite plans, according to CEO Peter Goldschmidt.

Surgeons at NYU Langone Health have transplanted a genetically engineered pig kidney that continues to function well after 32 days in a man declared dead by neurologic criteria and maintained with a beating heart on ventilator support.

Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23) being held September 9-12, 2023.

Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer.

AstraZeneca advances its robust lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, September 9-12, 2023.

ECRI, the nation’s largest independent patient safety organization, has been awarded a $80,000 grant from The AAMI Foundation to investigate the significance of isolation gown barrier penetration and identify ways to improve the protective features for healthcare workers and patients.

BrightEdge LLC, the American Cancer Society’s venture capital and impact investment arm, published its most recent annual report, featuring how its portfolio of 18 companies has the potential to improve the lives of more than 1.5 million cancer patients and their families.